ASPM (abnormal spindle-like microcephaly associated) is a gene on chromosome 1 that plays a central role in brain development. It provides instructions for building a protein that helps neural stem cells divide properly during embryonic growth. When both copies of the gene carry mutations, the result is a significantly smaller brain, a condition called primary microcephaly. ASPM is also the most commonly mutated gene among the known causes of this condition.
What the ASPM Protein Does
The ASPM protein works at the poles of the mitotic spindle, the internal scaffolding that pulls chromosomes apart when a cell divides. Its job is to keep the division plane oriented correctly in neural progenitor cells, the stem cells that eventually become the neurons of the cerebral cortex. When ASPM is functioning normally, these progenitor cells divide symmetrically: one stem cell splits into two identical stem cells, doubling the pool of cells available to build the brain.
When ASPM is reduced or absent, the division plane tilts. Instead of producing two identical stem cells, a progenitor cell is more likely to undergo asymmetric division, where one daughter cell becomes a stem cell and the other differentiates into a neuron too early. This premature differentiation shrinks the progenitor pool, and fewer total neurons are produced. The end result is a brain that is substantially smaller than normal, particularly in the cerebral cortex.
How It Connects to Brain Signaling
ASPM doesn’t operate in isolation. It acts as a positive regulator of the Wnt signaling pathway, one of the most important communication systems cells use during embryonic development. Wnt signaling promotes cell proliferation and helps maintain stem cell populations. When ASPM levels drop, Wnt-driven gene activity decreases, which further reduces the expansion of neural progenitors. In animal studies, artificially boosting Wnt signaling can partially rescue the brain growth deficits caused by ASPM loss, confirming the functional link between the two.
ASPM-Related Microcephaly
Mutations in both copies of the ASPM gene cause ASPM primary microcephaly (ASPM-MCPH), the most common genetic form of primary microcephaly. The condition is inherited in an autosomal recessive pattern, meaning a child must receive a defective copy from each parent. It is typically detected before birth on ultrasound, with head circumference measuring at least two standard deviations below the mean at birth and more than 3.5 standard deviations below the mean before age one.
The average reduction in brain volume is about 50%, affecting both the gray matter of the cortex and the underlying white matter. The shrinkage is most pronounced in the prefrontal and cingulate regions of the brain, while structures deeper in the temporal lobe are relatively spared. Importantly, children with ASPM-MCPH do not typically have other congenital abnormalities. The condition is largely confined to the brain.
Developmental milestones in young children are often normal, but intellectual disability becomes apparent as children grow older. The range is wide: some individuals have borderline-normal intellectual functioning, while others have severe disability. Memory tends to be relatively preserved. Several founder mutations have been identified across different populations, including specific variants common in Turkish, Pakistani, and European families.
A Role in Human Brain Evolution
The fact that ASPM mutations reduce brain size by roughly 70% in affected individuals drew the attention of evolutionary biologists. Analysis of the gene’s DNA sequence across primates revealed that ASPM underwent a period of accelerated evolution driven by positive natural selection after humans and chimpanzees diverged but before modern human populations separated from one another. Positive selection only acts on a gene when changes to its function increase an organism’s fitness, which strongly suggests that modifications to ASPM contributed to the expansion of the human cerebral cortex over evolutionary time.
ASPM in Cancer
Because ASPM is involved in cell division, its overexpression has consequences beyond the developing brain. The gene is abnormally active in several cancer types, including endometrial, prostate, and gastric cancers, as well as the childhood brain tumor medulloblastoma. In endometrial cancer, high ASPM expression is an independent predictor of shorter survival, with patients showing significantly worse outcomes compared to those with low expression. In prostate cancer, ASPM promotes tumor cell growth, migration, and invasion by amplifying Wnt signaling, the same pathway it regulates during normal brain development.
More recently, ASPM has been linked to drug resistance in lung cancer. In non-small cell lung cancer, ASPM stabilizes a key growth receptor on the cell surface, making tumors resistant to targeted therapies designed to block that receptor. When researchers knocked down ASPM in lab models, the receptor degraded faster and the cancer cells became sensitive to treatment again. This has positioned ASPM as a potential therapeutic target for overcoming drug resistance, though treatments aimed at ASPM are still in early investigation.
Genetic Testing and Diagnosis
Genetic testing for ASPM mutations is indicated when a child presents with congenital microcephaly, no other structural abnormalities, and brain imaging consistent with reduced cortical volume. The diagnosis is confirmed by identifying harmful variants in both copies of the gene through molecular testing, typically as part of a multigene panel that screens for all known microcephaly-associated genes simultaneously. For families with a known mutation, carrier testing and prenatal diagnosis are available. Because ASPM-MCPH accounts for the largest share of genetically confirmed primary microcephaly cases, it is often the first gene evaluated when other causes have been ruled out.